NARA Discovery
Article Details
← Back to Search Results
Journal Article

Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics

Mingxuan Ding; Kenta Teruya; Weiguanliu Zhang; Hae Weon Lee; Jue Yuan; Ayumi Oguma; Aaron Foutz; Manuel V. Camacho; Marcus Mitchell; Justin J. Greenlee; Qingzhong Kong; Katsumi Doh-ura; Li Cui; Wen-Quan Zou
Molecular Neurobiology · Vol. 58, Issue 9 · pp. 4280-4292 · 2021

Abstract

Previous studies have revealed that the infectious scrapie isoform of prion protein (PrP Sc ) harbored in the skin tissue of patients or animals with prion diseases can be amplified and detected through the serial protein misfolding cyclic amplification (sPMCA) or real-time quaking-induced conversion (RT-QuIC) assays. These findings suggest that skin PrP Sc -seeding activity may serve as a biomarker for the diagnosis of prion diseases; however, its utility as a biomarker for prion therapeutics remains largely unknown. Cellulose ethers (CEs, such as TC-5RW), widely used as food and pharmaceutical additives, have recently been shown to prolong the lifespan of prion-infected mice and hamsters. Here we report that in transgenic (Tg) mice expressing hamster cellular prion protein (PrP C ) infected with the 263K prion, the prion-seeding activity becomes undetectable in the skin tissues of TC-5RW-treated Tg mice by both sPMCA and RT-QuIC assays, whereas such prion-seeding activity is readily detectable in the skin of untreated mice. Notably, TC-5RW exhibits an inhibitory effect on the in vitro amplification of PrP Sc in both skin and brain tissues by sPMCA and RT-QuIC. Moreover, we reveal that TC-5RW is able to directly decrease protease-resistant PrP Sc and inhibit the seeding activity of PrP Sc from chronic wasting disease and various human prion diseases. Our results suggest that the level of prion-seeding activity in the skin may serve as a useful biomarker for assessing the therapeutic efficacy of compounds in a clinical trial of prion diseases and that TC-5RW may have the potential for the prevention/treatment of human prion diseases.

Bibliographic Information

JournalMolecular Neurobiology
PublisherSpringer
Publication Date2021-09-01
Publication Year2021
Volume58
Issue9
Pages4280-4292
Document TypeJournal Article
Print ISSN0893-7648
eISSN1559-1182
DOI10.1007/s12035-021-02418-6

Access Information

NARA Access Coverage1987-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12035
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.